Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as 2nd and 3rd or later-line treatment in metastatic colorectal cancer (MCRC) patients

被引：0
|
作者：
Samalin, E.
Lievre, A.
Boyer-Gestin, C.
Mitry, E.
Senesse, P.
Lepere, C.
Bachet, J.
Vaillant, J.
Rougier, J.
Ychou, M.
机构：
[1] Ccentre Aurelle, Montpellier, France
[2] Hop Ambroise Pare, Boulogne Billancourt, France
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：VII30 / VII30
页数：1
相关论文
共 50 条
  • [1] Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as second line, third-line or later treatment in metastatic colorectal cancer (MCRC) patients
    Lievre, A.
    Samalin, E.
    Senesse, P.
    Boyer-Gestin, C.
    Mitry, E.
    Lepere, C.
    Bachet, J.
    Vaillant, J.
    Ychou, M.
    Rougier, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Bang, Yeong Hak
    Kim, Jeong Eun
    Lee, Ji Sung
    Kim, Sun Young
    Kim, Kyu-Pyo
    Kim, Tae Won
    Hong, Yong Sang
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [3] Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yeong Hak Bang
    Jeong Eun Kim
    Ji Sung Lee
    Sun Young Kim
    Kyu-Pyo Kim
    Tae Won Kim
    Yong Sang Hong
    Scientific Reports, 11
  • [4] Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)
    Samalin, E.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Laurent-Puig, P.
    Ychou, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S418 - S418
  • [5] Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer
    Lee Chun Park
    Ho Sup Lee
    Seong Hoon Shin
    Seun Ja Park
    Moo In Park
    Sung Yong Oh
    Hyuk Chan Kwon
    Jin ho Baek
    Young Jin Choi
    Myoung Joo Kang
    Yang Soo Kim
    World Journal of Gastroenterology, 2012, (10) : 1104 - 1109
  • [6] Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer
    Park, Lee Chun
    Lee, Ho Sup
    Shin, Seong Hoon
    Park, Seun Ja
    Park, Moo In
    Oh, Sung Yong
    Kwon, Hyuk Chan
    Baek, Jin Ho
    Choi, Young Jin
    Kang, Myoung Joo
    Kim, Yang Soo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (10) : 1104 - 1109
  • [7] Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
    Samalin, E.
    Senellart, H.
    Thezenas, S.
    Jacquot, S.
    Ellis, S.
    Khemissa, F.
    Ramdani, M.
    Portales, F.
    Assenat, E.
    Mazard, T.
    Mineur, L.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] INTERIM ANALYSIS RESULTS OF MULTICENTRE PHASE II TRIAL ASSESSING SORAFENIB IN COMBINATION WITH IRINOTECAN AS 2ND OR LATER-LINE IN METASTATIC COLORECTAL CANCER PATIENTS WITH KRAS MUTATION (NEXIRI)
    Samalin, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 67
  • [9] Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients
    Bajetta, E
    Beretta, E
    Di Bartolomeo, M
    Cortinovis, D
    Ferrario, E
    Dognini, G
    Toffolatti, L
    Buzzoni, R
    ONCOLOGY, 2004, 66 (02) : 132 - 137
  • [10] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
12345